Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Maze Therapeutics, Inc.NASDAQ: MAZE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $24.21M (cash outflow) fell 26.2% year over year, ahead of the -335.9% change in trailing-twelve-month net income. Sequentially, it fell 30.0% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$109.05M (-16.8%) for the fiscal year ending Dec 2026, a step up from the -351.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.21M-30.0% QoQ
- Last fiscal yearDec 2025
- -$131.12M-351.0% YoY
- LTMMar 2026
- -$122.54M-335.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -26.2% | +29.6% | +55.8 pp |
| 1 year | -351.0% | -16.8% | +334.2 pp |
| 3-year CAGR | +4.5% | +24.6% | +20.1 pp |
| 5-year CAGR | -1.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (131.12M) USD
- Year-over-year change
- -351.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (131.12M) | -351.0% |
| FY2024 | 2024-12-31 | 52.23M | +152.0% |
| FY2023 | 2023-12-31 | (100.42M) | +12.6% |
| FY2022 | 2022-12-31 | (114.94M) | — |
Net Income vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -335.9% is the lowest of 8, against a peer median of +26.6%.
- Net income amounts to 612.7% of revenue for MAZE, versus a peer median of 41.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Sep 2026 | $146.22M USD | +65.1% | -57.4% | 22.5% | |
| LTM Mar 2026 | $122.54M USD | -335.9% | +4.5% | 612.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M USD | +26.6% | +26.6% | 871.8% |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M USD | +0.3% | +20.9% | 61.3% |
| LTM Mar 2026 | $58.06M USD | +8.0% | -2.9% | 13.6% | |
| LTM Jun 2026 | $38.38M USD | -106.1% | — | 3.8% | |
| LTM Mar 2026 | $35.1M USD | +30.0% | +33.8% | — | |
| Peer median (excluding MAZE) | — | +26.6% | +23.7% | 41.9% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.